ǰÑÔ
Ò»¸ö½ÏÁ¿¿¿½üÁÙ´²¡¢ÖØÏÖÐԺᢿɿصÄÄÔȱѪģ×Ó¹ØÓÚϵͳµØÑо¿ÄÔȱѪµÄ²¡ÀíÐÄÀí¼°ÊÓ²ìÒ©ÎïµÄÖÎÁÆ×÷ÓÃÊÇÊ®·ÖÖ÷ÒªµÄ¡£Æ¾Ö¤ÄÔѪ¹ÜµÄÆÊ½âÌØµã£¬ÄÔȱѪ(cerebral ischemia)Ä£×Óͨ³£¿É·ÖΪȫÄÔȱѪºÍ¾Ö²¿ÄÔȱѪÁ½´óÀ࣬ÆäÖÐÓÖ¿É·ÖΪÔÝʱȱѪºÍÓÀÊÀȱѪ¡£ÓÉÓÚ´óÊóÄÔѪ¹ÜÆÊ½â¡¢Éñ¾Ôª¿¿½ü¸ßµÈ¶¯Îï£¬ÖØÏÖÐԺ㬼ÛÇ®µÍÁ®£¬²¢ÇÒÓÉÓÚÆäÄÔ×é֯С£¬±ãÓÚÀä¶³ºó¾ÙÐÐÉú»¯¼ì²â£¬Òò´Ë£¬½üЩÄêÀ´¶àÓôóÊóÖÆ±¸ÄÔȱѪµÄÄ£×Ó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
È˵ÄÄÔѪ¹ÜÛÕ±ÕÒÔ´óÄÔÖж¯Âö×îΪ³£¼û£¬ÔÚ×è¶Ï´óÊó´óÄÔÖж¯Âöºó£¬¿ÉÒýÆð´óÄÔ°ëÇòƤ²ãºÍ»ùµ×ºËȱѪÐÔËðÉË£¬ÒÔº£ÂíCA1×îΪÃô¸Ð¡£ºÍÈ˵IJ¡Àí¸Ä±äÏàËÆ¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
²î±ðÆ·ÖÖ´óÊóÔÚ×è¶Ï´óÄÔÖж¯Âö(middle cerebral artery occlusion,MCAO)ºóÄÔ¹£ËÀÃæ»ý£¨Ìå»ý£©µÄ¾ÞϸºÍºã¶¨ÐÔ²î±ð£¬Sprague-Dawley´óÊó×îΪ³£Óá£MCAOÒýÆðµÄÄÔ¹£ËÀ¹æÄ£ÓëÄêËêÎ޹أ¬Ò»Ñùƽ³£ÓÃ250~350gÌåÖØµÄ´óÊó£¬êòĵ¾ù¿É£¬µ«ÒÔÐÛÐÔΪÒË¡£ÏÖÔÚ½ÏÁ¿±ê×¼ÒªÁìÊÇ£ºÒÔ12£¥Ë®ºÏÈýÂÈÒÒÈ©Âé×í(350mg/kg,ip)´óÊ󣬲àÎÔλÀο¿ÓÚÊÖÊǫ̃ÉÏ£¬Í·Æ¤Çпڣ¬ÊèÉ¢ò¨¼¡£¬È¡ÍâíöºÍÍâ¶úÃÅÁ¬ÏßµÄÖе㣬ÓÃÑÀ¿Æ×ê»ò»·ÐÎÂ×ê×꿪¹ǡ¢±©ÁØMCA£¬ÔÚÊÖÊõÏÔ΢¾µÏÂʶ±ð´óÄÔÖж¯Âö¼°Æä·ÖÖ§£¬ÔÚ·ÖÖ§µÄÏ·½¼´MCAµÄ½ü¶Î£¬ÊèÉ¢½áÔú»òÉÕׯMCA£¬×¢Öر£»¤ÄÔ×éÖ¯ÃâÊÜË𺦣¬È¡¾±²¿ÇпÚÊèÉ¢½áÔúͬ²àµÄ¾±×ܶ¯Âö(common carotid artery,CCA)¡£µçÄýʱΪ×èÖ¹µçÄý²»ÍêÈ«ËùÖµijöѪ£¬Ö»¹Ü½«MCAÌôÆð£¬Ê¹Ñª¹ÜÄÚѪÁ¿ïÔÌ¡£ÁíÍ⣬Ϊ±£»¤ÖÜΧ×éÖ¯ÃâÊÜׯÉË£¬¿ÉÓÃʪÃÞÇò±£»¤¡£×è¶Ï´óÄÔÖж¯ÂöºóÓÃС¿é¼¡Èâ×éÖ¯Çá·óÓÚ´°ÉÏ£¬È»ºóÖð²ã·ìºÏÉ˿ڣ¬Êõºó»ØÁýËÇÑø¡£ÒÔÉÏÀú³Ì¾ùÔÚÊÒκ㶨(24~25°C£©ÇéÐÎϾÙÐУ¬ÒÔÀûÓÚÆÀ¼ÛÄÔȱѪµÄˮƽ¡£È»ºóÓÃһС¿é¼¡ÈâÇá·ó¹Ǵ°¿Ú£¬Öð²ã·ìºÏºó£¬½«¶¯Îï·Å»ØÁýÖС£
¡¾Ä£×ÓÌØµã¡¿£º
±¾·¨ÊÖÊõÀÖ³ÉÂʸߣ¬ÈõµãΪ²Ù×÷½ÏÎªÖØ´ó¡£Æ¾Ö¤Ã¿Åú¶¯ÎïMCAµÄ²àÖ§¸»ºñˮƽ²î±ð£¬±¬·¢¹£ËÀÃæ»ýÔ¼ÔÚ15%~24%¡£×è¶ÏMCAµÄ²¿Î»Óë¹£ËÀÃæ»ýÓкܴó¹ØÏµ£¬½«¶¹×´ÎÆ×´Ì嶯ÂöºÍƤ²ã·ÖÖ§ÓëMCAÔ¶¶ËµÄ²àÖ§Ñ»·ÍÑÀ룬ÔÚMCAÆô³Ý´¦Óë´óÄÔϾ²ÂöÖ®¼ä£¬»òÐáÊøÍâ¶Ë2mm¿¿½üMCA²¿Î»ÉÕׯMCA½Ï³¤Ò»¶Î£¬Ôò¿ÉÒýÆð½Ïºã¶¨µÄ´óÄÔÆ¤²ãºÍ»ùµ×Éñ¾ºËÍŵĹ£ËÀ¡£ÈôÉÕׯ¿¿½üÐáÊøºÜ¶ÌÒ»¶ÎMCA£¬ÔòÖ»ÓÐ2/3¶¯Îï·ºÆðÄÔ¹£ËÀ¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ÓÉÓÚ´óÊóµÄÄÔѪ¹ÜÆÊ½âÌØµãÓëÈ˽Ͽ¿½ü£¬¸Ã·¨µÄ²¡ÀíÐÄÀíת±ä¿¿½üÈËÀàµÄMCA˨Èû¡£ÈõµãÊÇ¿ªÂÆÆËðÁËÂÄÚѹµÄºã¶¨£¬ÈÅÂÒÁËÄÔ¼¹ÒºÑ»·µÄ¶¯Á¦Ñ§£¬²¢Ò×ÖÂϸ¾úÇÖÈ룬´Ó¶øÓ°Ïì×éÖ¯²¡ÀíѧÆÀ¼Û¡£ÓÃMCAOÐγɴóÊó¾Ö²¿ÄÔȱѪÈÕÒæÊܵ½ÖØÊÓ£¬¿ÉÓÃÓÚ¶Ô´óÊóÄÔȱѪºó²¡ÀíÐÄÀíµÄÉîÈëÑо¿£¬²¢ÆÕ±éÓÃÓÚÆÀ¼Û¿¹ÄÔȱѪҩÎïµÄ×÷Ó㬵«ÎÞ·¨¾ÙÐÐÔÙ¹à×¢Ñо¿¡£
²Î¿¼ÎÄÏ×£º
1.Íõΰ£®ÑÏ¿á¿ØÖÆÊµÑéÌõ¼þ£¬½¨Éè±ê×¼»¯ÄÔȱѪ¶¯ÎïÄ£×Ó£®ÖлªÉñ¾¿ÆÔÓÖ¾£¬1998,31 (5):261-263
2.ÁõÅ馣¬¶ÅÑó£¬ÕÔÏþ·å£¬µÈ£®ÄÔȱѪ¶¯ÎïÄ£×ÓÖÆ±¸¼°Ó¦ÓÃÑо¿£®ÁÉÄþÖÐÒ½ÔÓÖ¾£¬2010,37 (6): 1151-1153
3.ºÎ½¨³É£¬ÆÖ±óºì£¬Ô½ð¡£¬µÈ£®¾ÖÔîÐÔÄÔȱѪ¶¯ÎïÄ£×ÓµÄÖÆ±¸¼°ÆÀ¼Û£®¸ÊËàÖÐҽѧԺѧ±¨£¬2001,18(1):55-57
4.ÕžùÌï. ÏÖ´úÒ©ÀíʵÑéÒªÁ죮±±¾©£º±±¾©Ò½¿Æ´óѧÖйúкÍÒ½¿Æ´óѧÍŽá³öÊéÉ磬2001
5.ÕÅÓµ²¨£¬ÇØÐÂÔ£¬ÍõµÃÐÂ. ¹æ·¶»¯ÄÔȱѪ¶¯ÎïÄ£×Ó£®ÄÔ×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾£¬2007,24(1):117-119
6.³ÂÜÔÏÒ£¬°½Àö¾ê£¬Àîçù£¬µÈ. ÄÔ×äÖж¯ÎïÄ£×ӵĽ¨ÉèÓë½ÏÁ¿£®Öйú¿µ¸´Ò½Ñ§ÔÓÖ¾£¬2011, 26 (8):779-782
7.ÐìÊåÔÆ£¬±åÈç奣¬³ÂÐÞ£®Ò©ÀíʵÑéÒªÁìѧ£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬2005
8.Krueger K, Busch E. Protocol of a tbromboernbolic stroke model in tbe ral: review of tbe experimental procedure and comparison of models. lnvesl Radio£¬2002, 37 (11):600- 608
9.Lestage P, Lockhart B,Roger A, el al. In vivo exploration of cerebral ischemia: use of neuroproteclive agents in animal studies. Therapie,2002,57(6):554-563